Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) ...

Shares of Instil Bio climbed after the company shared progress on a trial in China for its non-small cell lung cancer treatment in combination with chemotherapy and said it is preparing to start U.S.

The ENDEAVOUR lung cancer program, a three-year initiative designed to advance lung cancer research and care by connecting ...

Boehringer Ingelheim will present the latest data in its robust oncology pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including patient-reported outcomes (PRO) ...

The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.

CUHK researchers say drug D3S-001 can treat non-small cell lung, colorectal and pancreatic cancers triggered by gene mutation ...

From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide ...

Dr. Samuel Rosner, a thoracic oncologist at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, said a growing number of people, particularly women under 65, are ...

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum ...

Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of ...